MDEpiNet Annual Meeting | 10/22 and 10/23 Panel Sessions
NESTcc will participate in two panel sessions at the 10th MDEpiNet Annual Meeting. MDEpiNet is a public-private partnership bringing together leadership, expertise, and resources to build and operate in a national system that supports the development, regulation, and use of innovative medical devices.
On Oct. 22 at 8:10 a.m., NESTcc Executive Director Dr. Rachael Fleurence will present as part of the session titled Real World Evidence (RWE) and Evidence‐Based Decision Making. The title of her presentation is “MDEpiNet as a NEST Data Partner: Needs and Opportunities.”
Real World Evidence (RWE) and Evidence‐Based Decision Making
Panelists
- Rachael Fleurence, NESTcc
MDEpiNet as a NEST Data Partner: Needs and Opportunities - June Raine, MHRA
International Collaborations and Partnerships in Regulatory Setting: MHRA Perspective - Art Sedrakyan, Weill Cornell Medicine
Building Global Communities and Research Networks in Surgery, Interventions & Technologies
Moderators
- Danica Marinac-Dabic, FDA, and Scott Smith, HHS ASPE
Location:
FDA Headquarters
Building 31, Great Room
Silver Spring, MD
Registration:
Partnership Spotlight: NEST and MDEpiNet in 2020 and Beyond
On Oct. 23 at 8:10 a.m., NESTcc Data Network Director Dr. Robbert Zusterzeel will speak as part of the session titled Partnership Spotlight: NEST and MDEpiNet in 2020 and Beyond. The title of his presentation is: “An Update on NEST: From Real‐World Data to Real‐World Evidence.”
Panelists
- Jesse Berlin, Johnson & Johnson
Use of Healthcare Databases for Medical Device Assessment: J&J’s Experience with Databases and NEST Test-Cases
- Keith Marsolo, Duke University
Assessing Dataset Fitness with the NEST Data Quality Framework
- Julie Prillinger, Abbott
Using Real-World Data to Study Medical Devices: An Abbott Perspective
- Art Sedrakyan, Weill Cornell Medicine
NEST-Funded MDEpiNet Test-Cases
- Robbert Zusterzeel, NESTcc
An Update on NEST: From Real-World Data to Real-World Evidence
Moderator
- Owen Faris, FDA
